Your Employees Are Using GLP-1s For Things You've Never Heard of and it's About to Get Expensive

What started as dinner-party conversation has become one of the most expensive line items in an employer’s health plan.

GLP-1 prescriptions are expanding rapidly and are reshaping pharmacy budgets, renewals, and broker strategy.

According to modeling from the Employee Benefit Research Institute (EBRI), expanding GLP-1 coverage in employer health plans could drive premium increases between 5 to 14% under realistic utilization scenarios.

Most of the use cases for GLP-1s have revolved around weight loss, but that is only a fraction of their capabilities.

Medications like Ozempic, Wegovy, and Mounjaro aren't just for dropping pounds anymore. They're being prescribed (legitimately) for heart disease, kidney failure, sleep apnea, fatty liver disease, reducing inflammation, and conditions most plan sponsors have never connected to these medications.

If you thought weight loss prescriptions were expensive before, wait until you see what happens when GLP-1s become standard treatment for America's most costly chronic conditions.

Eight clinical uses driving GLP-1 prescriptions that have nothing to do

with weight loss

To understand why prescribing continues to expand, employers need to understand which conditions physicians are now treating.

FDA approved clinical uses:

1. Preventing heart attacks in diabetics

   In patients with type 2 diabetes and cardiovascular disease, semaglutide has been shown to reduce major cardiovascular events by approximately 20-26% in large outcome trials such as SUSTAIN-6 and SELECT.

   
   

2. Keeping people off dialysis

   The FLOW trial, published in the New England Journal of Medicine demonstrated that semaglutide reduced major kidney disease events by approximately 24% in patients with type 2 diabetes and chronic kidney disease.

   
   

3. Improving fatty liver disease

   An estimated 30-40% of U.S. adults have non-alcoholic fatty liver disease (NAFLD), and roughly 1 in 5 progress to non-alcoholic steatohepatitis (NASH), which can lead to cirrhosis and liver failure. In a landmark New England Journal of Medicine trial, 59% of patients treated with semaglutide achieved NASH resolution, compared to 17% on placebo, along with substantial reductions in liver fat.

   
   

4. Treating sleep apnea

   Zepbound was used to treat moderate-to-severe obstructive sleep apnea in patients with obesity in 2024. In the SURMOUNT-OSA trial, published in the New England Journal of Medicine, tirzepatide reduced apnea-hypopnea index events by up to 55–63% compared to a placebo. Obstructive sleep apnea affects an estimated 30 million Americans and is linked to increased cardiovascular risk, workplace accidents, and lost productivity.

   
   

5. Managing type 2 diabetes (the original use)

   Average A1C reductions of 1.5-2.0% better than most oral diabetes medications. Better control means fewer amputations, less blindness, fewer infections, and reduced cardiovascular complications.

Emerging and off label uses:

6. Reducing inflammation

   Emerging research shows reductions in C-reactive protein and other inflammatory markers by 20-40%. Potential applications include arthritis, autoimmune conditions, and chronic pain syndromes.

   
   

7. Addiction treatment

   Some evidence that GLP-1s may reduce cravings for alcohol, opioids, and nicotine. These trials are still ongoing and may be years away from coverage decisions.

   
   

8. PCOS and infertility

   Polycystic ovary syndrome affects up to 10% of women of reproductive age. GLP-1s show improvements in menstrual regularity, androgen levels, and metabolic markers.

This category is still evolving. Lilly and other manufacturers already have next-generation GLP-1 drugs in late-stage trials, and new indications are being studied for some of the highest-cost chronic conditions in employer plans. Not every trial will lead to approval, and coverage rules will continue to change, but the direction is clear: the GLP-1 conversation is no longer just about weight loss. For self-funded employers, it's becoming a risk-management issue.

The financial reality for self-funded employers

GLP-1 medications often cost $10,000 to $15,000 per member, per year. In a self-funded model, these costs do not wait for renewals. They hit claims immediately, increase stop-loss exposure, and alter long-term financial projections. Growing clinical exposure is serious. But the way these drugs are purchased is what makes it dangerous.

Many Prescription Benefit Manager (PBM) contracts are structured around rebates tied to high list prices. The larger the list price, the larger the rebate. Simply put, the rebates only look impressive because the starting price was artificially inflated in the first place.

A large rebate can feel like savings. But if the drug could have been sourced for less another way, it was never real savings to begin with. And when a medication costs up to $15,000 per member per year, small pricing gaps can snowball into real plan damage.

Apta Rx: A different way to purchase high-cost prescriptions

At its core, prescription purchasing is a fiduciary obligation. Apta Rx is designed to ensure that responsibility is met with transparency.

Employer groups with 200 lives realize an average of $572,000 in annual prescription savings by correcting inefficiencies embedded in other pharmacy models.

Here's how that structure works:

1. A lowest net cost strategy

Traditional pharmacy contracts prioritize list price and rebate strategies, creating misaligned incentives around high-cost drugs. Apta Rx evaluates every prescription based on true net cost, meaning what the employer pays after pass-through and transparent rebates, generics, cash pricing, alternative funding, and all sourcing pathways are considered.

The objective is simple: purchase the drug at the lowest defensible net cost for the plan and the member.

2. Independent clinical oversight

Apta Rx separates clinical decisions from purchasing and rebate incentives. An independent clinical team evaluates each case for medical necessity, appropriate dosing, therapeutic alternatives, and ongoing effectiveness. Their role is to determine what is clinically appropriate, not what is financially convenient.

This structure avoids two common failures by PBM's: automatic approvals driven by demand and denials driven purely by cost.

3. Smarter access to specialty and high-cost drugs

GLP-1s are part of a broader specialty trend. Apta Rx leverages biosimilars, international sourcing, alternative funding options, and alternative distribution channels to reduce costs without compromising safety or quality.

Traditional PBM structures rarely present these options transparently.

4. Customization for each company

Prescription strategy cannot be one size fits all. Workforce demographics, chronic condition prevalence, stop-loss structure, and risk tolerance all matter.

Apta Rx designs employer-specific pharmacy strategies that integrate into all Apta Health's programs. Prescription management aligns with overall population health goals, cost containment priorities, and long-term financial planning.

What about federal drug pricing reform?

Federal policymakers on both sides of the aisle have proposed reforms aimed at increasing drug price transparency, limiting certain PBM practices, and negotiating prices within government programs.

Some changes are already underway within Medicare and additional reforms may influence the pharmaceutical market over time. However, most federal drug pricing reforms apply first to government programs and do not automatically reduce costs for self-funded employer plans.

Regardless of policy shifts, employers remain responsible for how prescription drugs are purchased and managed within their own plans. Specialty drug spend is influenced as much by contract structure and sourcing strategy as it is by federal pricing policy.

Your company's next strategic shift

GLP-1s are not a temporary spike in pharmacy spend. They reflect a significant shift in how chronic disease is treated and financed.

Employers are often told the price is the price. When, in fact, it isn't. How these medications are purchased, evaluated, and managed determines whether they destabilize a plan or strengthen it.

Apta Rx applies lowest net cost, independent clinical decision-making, and alternative sourcing strategies to specialty drug purchasing. The impact is measurable: employer groups with 200 lives realize an average of $572,000 in annual prescription savings without restricting clinically appropriate care.

Apta Health conducts in-depth prescription analyses that identify exactly what is driving cost within your plan, including specialty drug exposure, sourcing inefficiencies, and contract misalignment.

If you have not completed a comprehensive prescription review in the past 12 months, that is where the conversation should begin. Contact our team to start today.